China Universal Asset Management Company’s RAPT Therapeutics RAPT Stock Holding History

China Universal Asset Management Company’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,515	Closed	-$153K	–	517
2025 Q4	$153K	Buy	+4,515	New	+$140K	0.01%	372
2024 Q4	–	Sell	-839	Closed	-$13.5K	–	519
2024 Q3	$13.5K	Buy	839 +326	+64%	+$6.59K	﹤0.01%	414
2024 Q2	$12.5K	Sell	513 -312	-38%	-$14.4K	﹤0.01%	399
2024 Q1	$59.3K	Buy	825 +327	+66%	+$45.5K	0.01%	406
2023 Q4	$98.9K	Buy	498 +387	+349%	+$47.9K	0.02%	281
2023 Q3	$14.8K	Buy	111 +55	+98%	+$8.98K	﹤0.01%	316
2023 Q2	$8.41K	Sell	56 -2	-3%	-$312	﹤0.01%	330
2023 Q1	$8.44K	Buy	58 +15	+35%	+$3.03K	﹤0.01%	316
2022 Q4	$6.83K	Buy	43 +8	+23%	+$1.28K	﹤0.01%	263
2022 Q3	$7K	Buy	+35	New	+$6.62K	﹤0.01%	236

China Universal Asset Management Company's RAPT Position: Q1 2026 in Review

China Universal Asset Management Company sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 4,515 shares — an estimated $153K sold.

China Universal Asset Management Company first reported a position in RAPT in Q3 2022 and held it in 10 quarters. The position peaked at $153K in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

China Universal Asset Management Company reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
China Universal Asset Management Company sold 4,515 RAPT Therapeutics shares in Q1 2026, an estimated $153K.
China Universal Asset Management Company first reported a position in RAPT Therapeutics in Q3 2022 and held it in 10 quarters.
China Universal Asset Management Company's RAPT Therapeutics position peaked at $153K in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on China Universal Asset Management Company's 13F filing for Q1 2026, filed 28 Apr 2026.